Source Pravda.Ru

India’s Ranbaxy won approval to make and sell the anti-diabetes drug in U.S.

Indian pharmaceutical giant Ranbaxy said Friday it had received final approval from the U.S. Food and Drug Administration to make and sell the anti-diabetes drug glimipiride in the United States.

Glimepiride is the generic equivalent of Sanofi Aventis SA's anti-diabetic agent Amaryl, whose patent just expired. The brand has annual sales of about $350 million (Ђ287 million). Officials at the FDA and Aventis could not be immediately reached for comment.

Ranbaxy said in a statement that it had received approval to sell the tablets in doses of 1 milligram, 2 milligrams, 3 milligrams, 4 milligrams, 6 milligrams and 8 milligrams, reports the AP. I.L.

Comments
100th anniversary of Great October Revolution: Celebrating mountain of errors
ISIS threatens to conduct large-scale terrorist attacks in USA for Jerusalem decision
ISIS threatens to conduct large-scale terrorist attacks in USA for Jerusalem decision
North Korea says Trump makes first step towards nuclear war
North Korea says Trump makes first step towards nuclear war
North Korea says Trump makes first step towards nuclear war
North Korea says Trump makes first step towards nuclear war
Capitalism reduced Indonesian cities to infested carcases
Tel Aviv, Jerusalem, capitals and puppets
ISIS threatens to conduct large-scale terrorist attacks in USA for Jerusalem decision
No one can intercept Kim Jong-un's invincible ballistic missiles
Torturing Jerusalem with USA's help: No peace, but eternal war for Jews and Arabs
North Korea is not a threat to the US
North Korea is not a threat to the US
Torturing Jerusalem with USA's help: No peace, but eternal war for Jews and Arabs
Tel Aviv, Jerusalem, capitals and puppets
North Korea is not a threat to the US
North Korea is not a threat to the US
North Korea is not a threat to the US
Putin: Russia will continue spending enough on defence not to be killed
Putin: Russia will continue spending enough on defence not to be killed